The effect of spiramycin in prevention of toxoplasma infection in neonates

Not Applicable

• Conditions: Congenital Toxoplasmosis.; Congenital toxoplasmosis; P37.1

• Registration Number: IRCT20170201032346N5
• Lead Sponsor: Ramsar Campus, Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Positive Anti-Toxoplasma gondii IgG and IgM antibodies
Signed informed consent

Exclusion Criteria

High positive avidity test
Negative Anti-Toxoplasma gondii IgM antibodies
Positive screening tests for fetal anomalies

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of congenital toxoplasmosis. Timepoint: Evaluation of infant until a year after birth. Method of measurement: Physical examination and performing diagnostic tests based on patient complaint.;Fetal abortion. Timepoint: from diagnosis and initiation of treatment until delivery. Method of measurement: History, physical examination and sonography.